七组抗菌药物治疗支气管扩张合并感染的对比研究

Comparative Study on Seven Groups of Antibiotics in Treatment of Bronchiectasis Complicated with Infections

目的:探讨七组抗菌药物治疗支气管扩张合并感染的疗效,以筛选出疗效好、花费少的治疗方案。方法:选取2014年7月—2015年12月宣城市人民医院收治的支气管扩张合并感染患者111例作为研究对象,以随机数字表法分为A组(阿莫西林克拉维酸钾+左氧氟沙星)15例、B组(阿莫西林克拉维酸钾+阿奇霉素)15例、C组(头孢米诺+阿米卡星)15例、D组(头孢哌酮舒巴坦+阿米卡星)17例、E组(头孢哌酮舒巴坦+左氧氟沙星)19例、F组(头孢他啶+阿米卡星)15例、G组(头孢他啶+左氧氟沙星)15例,共七组。观察七组患者的临床疗效、住院时间、抗菌药物费用及不良反应发生情况。结果:D、E、F、G组患者的总有效率均>90%,且该四组患者总有效率的差异无统计学意义(P>0.05)。排除无效病例后,组间比较,七组患者住院时间的差异无统计学意义(P>0.05)。D组患者抗菌药物费用最低,其次为F组,D、F组患者抗菌药物费用的差异无统计学意义(P>0.05)。C、D、F组患者不良反应发生率最低,与其他各组比较,差异均有统计学意义(P<0.05)。结论:头孢他啶联合阿米卡星治疗支气管扩张合并感染的疗效最好、住院时间最短、抗菌药物费用较低、住院总费用最低、不良反应最少。

OBJECTIVE：To probe into the efficacy of seven groups of antibiotics in treatment of bronchiectasis complicated with infections, so as to screen out the therapeutic regimen with significant efficacy and low costs. METHODS ： 111 patients with bronchiectasis complicated with infections admitted into People＇ s Hospital of Xuancheng from Jul. 2014 to Dec. 2015 were selected to be divided into group A （amoxicillin potassium clavulanate ＋ levofloxacin） with 15 cases, group B （amoxicillin potassium clavulanate ＋ azithromycin） with 15 cases, group C （cefminox ＋ amikacin） with 15 cases, group D （cefoperazone sulbactam ＋ amikacin） with 17 cases, group E （cefoperazone sulbactam ＋ levofloxacin） with 19 cases, group F （ceftazidime ＋ amikacin） with 15 cases and group G （ceftazidime ＋ levofloxacin） with 15 cases via the random number table. The clinical efficacy, length of hospital, antibiotics costs and incidence of adverse drug reactions of seven groups were observed. RESULTS： The total effective rates of group D, E, F, G were all 〉90%, and there was no statistical significance among four groups（P 〉0. 05）. Except for invalid cases, there was no statistical significance among seven groups（P 〉0.05 ）. The antibiotics costs of group D were the lowest, followed by group F, there was no statistical significance between group D and F （ P 〉 0. 05 ）. The incidences of adverse drug reactions in group C, D and F were the lowest, compared with other groups, the difference was statistically significant （P 〈 0. 05 ）. CONCLUSIONS： The efficacy of ceftazidime ＋ amikacin in treatment of bronchiectasis complicated with infections is significant, with shortest length of hospital, lowest antibiotics costs, lowest total hospital costs and fewer adverse drug reactions.